Rational design of an organometallic glutathione transferase inhibitor
about
Diuretic drug binding to human glutathione transferase P1-1: potential role of Cys-101 revealed in the double mutant C47S/Y108VA ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome coreHuman carbonic anhydrase II as a host for piano-stool complexes bearing a sulfonamide anchorMapping the protein-binding sites for iridium(iii)-based CO-releasing moleculesExpression proteomics study to determine metallodrug targets and optimal drug combinations.Bivalent enzyme inhibitors discovered using dynamic covalent chemistry.Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MSNovel C,N-chelate rhodium(III) and iridium(III) antitumor complexes incorporating a lipophilic steroidal conjugate and their interaction with DNA.Organometallic anticancer compoundsAltered DNA binding and amplification of human breast cancer suppressor gene BRCA1 induced by a novel antitumor compound, [Ru(η(6)-p-phenylethacrynate)Cl(2)(pta)].Targeted and multifunctional arene ruthenium chemotherapeutics.Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies.Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands.Selenoquinones stabilized by ruthenium(II) arene complexes: synthesis, structure, and cytotoxicity.Carbohydrate linked organotin(IV) complexes as human topoisomerase Iα inhibitor and their antiproliferative effects against the human carcinoma cell line.Synthesis and evaluation of new polynuclear organometallic Ru(II), Rh(III) and Ir(III) pyridyl ester complexes as in vitro antiparasitic and antitumor agents.Ruthenium-Arene-β-Carboline Complexes as Potent Inhibitors of Cyclin-Dependent Kinase 1: Synthesis, Characterization and Anticancer Mechanism Studies.Self-assembled metalla-rectangles bearing azodipyridyl ligands: synthesis, characterization and antitumor activity.Targeting the DNA-topoisomerase complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent DNA binder.A bifunctional organometallic ruthenium drug with multiple modes of inducing apoptosis.Arene ruthenium complexes as anticancer agents.Metal-based antitumour drugs in the post-genomic era: what comes next?"Inverse Drug Discovery" Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates.Protein metalation by metal-based drugs: X-ray crystallography and mass spectrometry studies.Complexation with organometallic ruthenium pharmacophores enhances the ability of 4-anilinoquinazolines inducing apoptosis.Glutathione transferase P1-1 as an arsenic drug-sequestering enzyme.A general strategy to add diversity to ruthenium arene complexes with bioactive organic compounds via a coordinated (4-hydroxyphenyl)diphenylphosphine ligand.Ruthenium(ii) arene NSAID complexes: inhibition of cyclooxygenase and antiproliferative activity against cancer cell lines.Organoruthenium antagonists of human A₃ adenosine receptors.In Vitro Inhibition of Human Placental Glutathione S-Transferase by 3-Arylcoumarin Derivatives.Ruthenium arene complexes with triphenylphosphane ligands: cytotoxicity towards pancreatic cancer cells, interaction with model proteins, and effect of ethacrynic acid substitution
P2860
Q27662171-191FCC0F-60DF-4BD7-8162-0D9F68AC8F8BQ27666776-0E00C2DF-2EFF-497D-8468-39C02F31624CQ27670566-9B0390B9-5D08-4AB0-B89A-E1ED939FC9B5Q27719016-9D7AFED1-FAB9-470E-A09F-5C4A4C1167E9Q33685955-51700C46-257E-459E-A7F4-B5AE1F6E962CQ34287232-CFB3CC98-B1FC-4C71-83E6-2A6814F0E101Q34394993-C5734FD1-8467-4A9F-8829-D5BDB7C6FD7FQ34415646-C161B10D-6667-4030-8DBF-2C33C2E80406Q34476685-1AF186BF-82BF-45E3-801A-E5ED586928A2Q36396542-C488C66A-A569-498D-A1C4-CECC9B6C5412Q37920741-6D91437D-CAB4-4247-AA5A-32BA04993EE3Q38699445-CAD9B0B1-D327-43AB-B1B0-945E40AE3613Q38860575-B60BE715-EABD-4689-B834-1386B78E894BQ39011714-5A7BDFAE-55AC-4DF7-A671-6082E4C0D3D1Q39047919-E473198C-2502-43AA-AFC4-A656D21B6E6EQ39079789-2CC10459-6EB9-40A3-A597-C20BEC3752C6Q39121561-769EE9E1-6B48-41FF-B8FD-17314136C502Q39257995-AEDDC1DF-716E-4CF3-ADC4-A6D1448FBDE7Q39365214-84CFE3C5-D519-4181-B4B9-EB729C8C0BFBQ39570737-A6F7A503-2D6B-4A87-A278-F1D0E3BA1A52Q39706669-3CFF1117-486F-4C5A-8D6A-290780DF84F5Q39732756-5F9C3DE4-7710-4964-A62E-203D6B0F0747Q47266601-F31B412C-E43D-4E46-B07F-0379DF35ABD3Q47667663-576AA26B-23B8-4DEE-ACC8-4D221C8F7B80Q48002370-18C963C7-A058-4F71-8718-EC8F699A6E4EQ48214407-6EBAD544-0E14-432E-813A-0E57FF28C431Q48259223-5AA33431-4ADE-470E-8697-0939D92B6AF7Q49860442-A373E727-4CD4-46E2-B3BA-016B8E71A699Q51047023-F2304C26-06A7-4E8F-A803-7DE8F8178A04Q53830611-1DE3687D-DAB2-46DC-8CF8-12B15D7B1862Q58856038-4989AE03-8E60-44DA-8B44-B943C864082B
P2860
Rational design of an organometallic glutathione transferase inhibitor
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Rational design of an organometallic glutathione transferase inhibitor
@ast
Rational design of an organometallic glutathione transferase inhibitor
@en
Rational design of an organometallic glutathione transferase inhibitor
@nl
type
label
Rational design of an organometallic glutathione transferase inhibitor
@ast
Rational design of an organometallic glutathione transferase inhibitor
@en
Rational design of an organometallic glutathione transferase inhibitor
@nl
prefLabel
Rational design of an organometallic glutathione transferase inhibitor
@ast
Rational design of an organometallic glutathione transferase inhibitor
@en
Rational design of an organometallic glutathione transferase inhibitor
@nl
P2093
P50
P356
P1476
Rational design of an organometallic glutathione transferase inhibitor
@en
P2093
Lorien J Parker
Lucienne Juillerat-Jeanneret
Mario Lo Bello
P304
P356
10.1002/ANIE.200900185
P407
P577
2009-01-01T00:00:00Z